Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
|Articles|July 30, 2014
- NSCLC (Issue 3)
- Volume 3
- Issue 1
Adverse Events Associated With CO-1686
Author(s)Lecia V. Sequist, MD
Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses adverse events (AEs) associated with CO-1686 for patients with non-small cell lung cancer (NSCLC).
Advertisement
Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses adverse events (AEs) associated with the novel EGFR inhibitor CO-1686 for patients with non-small cell lung cancer (NSCLC).
View more on other next-generation therapies for NSCLC > >
Articles in this issue
about 12 years ago
Update on Next-Generation Therapies for NSCLCabout 12 years ago
Cabozantinib Plus Erlotinib for Advanced EGFR-Mutant NSCLCabout 12 years ago
<em>RICTOR</em> Amplification in Lung Cancerabout 12 years ago
Peer Discussion on Maintenance Therapy in NSCLCabout 12 years ago
Trials of Anti-PD-L1 in NSCLC Are Well Under WayAdvertisement
Related to this article
During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
4
Has CAR T Access Improved 1 Year After REMS Elimination?
5